<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36969241</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative.</ArticleTitle><Pagination><StartPage>1129459</StartPage><MedlinePgn>1129459</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1129459</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1129459</ELocationID><Abstract><AbstractText>Although most individuals recover from acute SARS-CoV-2 infection, a significant number continue to suffer from Post-Acute Sequelae of SARS-CoV-2 (PASC), including the unexplained symptoms that are frequently referred to as long COVID, which could last for weeks, months, or even years after the acute phase of illness. The National Institutes of Health is currently funding large multi-center research programs as part of its Researching COVID to Enhance Recover (RECOVER) initiative to understand why some individuals do not recover fully from COVID-19. Several ongoing pathobiology studies have provided clues to potential mechanisms contributing to this condition. These include persistence of SARS-CoV-2 antigen and/or genetic material, immune dysregulation, reactivation of other latent viral infections, microvascular dysfunction, and gut dysbiosis, among others. Although our understanding of the causes of long COVID remains incomplete, these early pathophysiologic studies suggest biological pathways that could be targeted in therapeutic trials that aim to ameliorate symptoms. Repurposed medicines and novel therapeutics deserve formal testing in clinical trial settings prior to adoption. While we endorse clinical trials, especially those that prioritize inclusion of the diverse populations most affected by COVID-19 and long COVID, we discourage off-label experimentation in uncontrolled and/or unsupervised settings. Here, we review ongoing, planned, and potential future therapeutic interventions for long COVID based on the current understanding of the pathobiological processes underlying this condition. We focus on clinical, pharmacological, and feasibility data, with the goal of informing future interventional research studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Bonilla, Peluso, Rodgers, Aberg, Patterson, Tamburro, Baizer, Goldman, Rouphael, Deitchman, Fine, Fontelo, Kim, Shaw, Stratford, Ceger, Costantine, Fisher, O&#x2019;Brien, Maughan, Quigley, Gabbay, Mohandas, Williams and McComsey.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonilla</LastName><ForeName>Hector</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine and Infectious Diseases, Stanford University, Palo Alto, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medicine and Infectious Diseases, University of California, San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodgers</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Innovations in Brain Science, University of Arizona, Tucson, AZ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aberg</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Infectious Diseases, Icahn School of Medicine at Mount Sinai, Chief, Division of Infectious Disease, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamburro</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Intramural Research, National Institute of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baizer</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Heart Lung and Blood Institute, Division of Lung Diseases, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Organ Transplant and Liver Center, Swedish Medical Center, Seattle, WA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouphael</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deitchman</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fine</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine at New York University (NYU) Grossman School of Medicine, Physical Medicine and Rehabilitation Service, New York University (NYU), New York University Medical Center, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontelo</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Applied Clinical Informatics Branch, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Arthur Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Medicine at Harvard Medical School, Division of Infectious Disease, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Gwendolyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Triangle Institute (RTI), International, Durham, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stratford</LastName><ForeName>Jeran</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Triangle Institute (RTI), International, Durham, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceger</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Triangle Institute (RTI), International, Durham, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantine</LastName><ForeName>Maged M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Liza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Long COVID Families, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Utah Covid-19 Long Haulers, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maughan</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Utah Covid-19 Long Haulers, Salt Lake City, UT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>John G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabbay</LastName><ForeName>Vilma</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohandas</LastName><ForeName>Sindhu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McComsey</LastName><ForeName>Grace A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Medicine, Case Western Reserve University, Cleveland, OH, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS- CoV-2</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">long haulers</Keyword><Keyword MajorTopicYN="N">post-acute sequela of SARS-CoV-2 (PASC)</Keyword><Keyword MajorTopicYN="N">recover</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36969241</ArticleId><ArticleId IdType="pmc">PMC10034329</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1129459</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. . Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - united states, march-June 2020. MMWR Morb Mortal Wkly Rep (2020) 69(30):993&#x2013;8. doi:&#xa0;10.15585/mmwr.mm6930e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A, Kudryavtsev I, Starshinova A, Kudlay D, Zinchenko Y, Glushkova A, et al. . Post COVID-19 syndrome in patients with Asymptomatic/Mild form. Pathogens (2021) 10(11). doi:&#xa0;10.3390/pathogens10111408</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10111408</ArticleId><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC . National center for immunization and respiratory diseases (NCIRD) DoVD. long COVID or post-COVID conditions (2022). Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/.</Citation></Reference><Reference><Citation>
National Institute for Health and Care Excellence (NICE) S, of IGNSaRC, (RCGP) GP . COVID-19 rapid guideline: Managing the long-term effects of COVID-19 (2022). Available at: https://www.nice.org.uk/guidance/ng188.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. Condition WHOCCDWGoP-c-. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis (2022) 22(4):e102&#x2013;e7. doi:&#xa0;10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>
(AAPM&amp;R) TAAoPMaR . Post-acute sequelae of SARS-CoV-2 infection (PASC) estimates and insights. dashboard (2022). Available at: https://pascdashboard.aapmr.org/.</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review. J Infect Dis (2022) 226. doi:&#xa0;10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens (2022) 11(2). doi:&#xa0;10.3390/pathogens11020269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: A meta-analysis and systematic review. J Infect Dis (2022) 226(9):1593&#x2013;607. doi: 10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC . National center for health statistics. nearly one in five American adults who have had COVID-19 still have &#x201c;Long COVID&#x201d; (2022). Available at: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm.</Citation></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol (2022) 43(4):268&#x2013;70. doi: 10.1016/j.it.2022.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J. Clues to long COVID. Science (2022) 376(6599):1261&#x2013;5. doi: 10.1126/science.add4297</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.add4297</ArticleId><ArticleId IdType="pubmed">35709281</ArticleId></ArticleIdList></Reference><Reference><Citation>
NIH . Understanding COVID-19 vaccines. which COVID-19 vaccines are available in the united states? (2022). Available at: https://covid19.nih.gov/covid-19-vaccines.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med (2021) 384(5):403&#x2013;16. doi: 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle LM, Kotloff KL, Gay CL, Anez G, Adelglass JM, Barrat Hernandez AQ, et al. . Efficacy and safety of NVX-CoV2373 in adults in the united states and Mexico. N Engl J Med (2022) 386(6):531&#x2013;43. doi: 10.1056/NEJMoa2116185</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116185</ArticleId><ArticleId IdType="pmc">PMC8693692</ArticleId><ArticleId IdType="pubmed">34910859</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC . National center for immunization and respiratory diseases (NCIRD), division of viral Diseases Benefits of getting a COVID-19 vaccine (2022). Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html.</Citation></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The protective effect of coronavirus disease 2019 (COVID-19) vaccination on postacute sequelae of COVID-19: A multicenter study from a Large national health research network. Open Forum Infect Dis (2022) 9(7):ofac228. doi: 10.1093/ofid/ofac228</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac228</ArticleId><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med (2022) 28(7):1461&#x2013;7. doi: 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y CT, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. MedRxiv (2022). doi:&#xa0;10.1101/2022.11.03.22281783v1</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.03.22281783v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevalainen OPO, Horstia S, Laakkonen S, Rutanen J, Mustonen JMJ, Kalliala IEJ, et al. . Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun (2022) 13(1):6152. doi: 10.1038/s41467-022-33825-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33825-5</ArticleId><ArticleId IdType="pmc">PMC9579198</ArticleId><ArticleId IdType="pubmed">36257950</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L, Meli G, Poletti F, Rostagno R, Moglia R, Cantone M, et al. . Risk factors and incidence of long-COVID syndrome in hospitalized patients: Does remdesivir have a protective effect? QJM (2022) 114(12):865&#x2013;71. doi: 10.1093/qjmed/hcab297</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. . Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med (2020) 383(23):2291&#x2013;3. doi: 10.1056/NEJMc2031364</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F, Catalan P, Rodriguez-Grande C, Adan J, Rodriguez-Gonzalez C, Munoz P, et al. . Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis (2022) 22(1):211. doi:&#xa0;10.1186/s12879-022-07153-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. . Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (NY). (2022) 3(6):371&#x2013;87 e9. doi: 10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rossler A, et al. . Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology (2022) 163(2):495&#x2013;506.e8. doi: 10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, et al. . SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann Neurol (2022) 91(6):772&#x2013;81. doi: 10.1002/ana.26350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. . Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis (2022) 76. doi: 10.1101/2022.06.14.22276401</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.14.22276401</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V MA, Krishnamachary B, Spikes L, Chalise P, Dhillon NK. Persistent presence of spike protein and viral RNA in the circulation of individuals with post-acute sequelae of COVID-19. MedRxiv (2022). doi:&#xa0;10.1101/2022.08.07.22278520v1</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.07.22278520v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Remmelink M, De Mendonca R, D&#x2019;Haene N, De Clercq S, Verocq C, Lebrun L, et al. . Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care (2020) 24(1):495. doi: 10.1186/s13054-020-03218-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03218-5</ArticleId><ArticleId IdType="pmc">PMC7422463</ArticleId><ArticleId IdType="pubmed">32787909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D SS, Ramelli S, Grazioli A, Chung JY, Singh M, Yinda CK, et al. . SARS-CoV-2 infection and persistence throughout the human body and brain. Res Square (2021). doi: 10.21203/rs.3.rs-1139035/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Badran Z, Gaudin A, Struillou X, Amador G, Soueidan A. Periodontal pockets: A potential reservoir for SARS-CoV-2? Med Hypotheses (2020) 143:109907. doi: 10.1016/j.mehy.2020.109907</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109907</ArticleId><ArticleId IdType="pmc">PMC7833827</ArticleId><ArticleId IdType="pubmed">32504927</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. . SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature (2022) 612, 1&#x2013;6. doi: 10.1038/s41586-022-05542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv T, Cao W, Li T. HIV-Related immune activation and inflammation: Current understanding and strategies. J Immunol Res (2021) 2021:7316456. doi: 10.1155/2021/7316456</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/7316456</ArticleId><ArticleId IdType="pmc">PMC8494587</ArticleId><ArticleId IdType="pubmed">34631899</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, et al. . B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med (2015) 21(2):132&#x2013;9. doi: 10.1038/nm.3781</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3781</ArticleId><ArticleId IdType="pmc">PMC4320022</ArticleId><ArticleId IdType="pubmed">25599132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, et al. . Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest. (2012) 122(9):3271&#x2013;80. doi: 10.1172/JCI64314</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI64314</ArticleId><ArticleId IdType="pmc">PMC3428098</ArticleId><ArticleId IdType="pubmed">22922259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenchley JM, Vinton C, Tabb B, Hao XP, Connick E, Paiardini M, et al. . Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood (2012) 120(20):4172&#x2013;81. doi: 10.1182/blood-2012-06-437608</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-06-437608</ArticleId><ArticleId IdType="pmc">PMC3501715</ArticleId><ArticleId IdType="pubmed">22990012</ArticleId></ArticleIdList></Reference><Reference><Citation>Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al. . HIV-Associated neurocognitive disorder&#x2013;pathogenesis and prospects for treatment. Nat Rev Neurol (2016) 12(4):234&#x2013;48. doi: 10.1038/nrneurol.2016.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.27</ArticleId><ArticleId IdType="pmc">PMC4937456</ArticleId><ArticleId IdType="pubmed">26965674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis (2012) 205 Suppl 3(Suppl 3):S375&#x2013;82. doi: 10.1093/infdis/jis200</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis200</ArticleId><ArticleId IdType="pmc">PMC3349295</ArticleId><ArticleId IdType="pubmed">22577211</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Berg PJ, Heutinck KM, Raabe R, Minnee RC, Young SL, van Donselaar-van der Pant KA, et al. . Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis (2010) 202(5):690&#x2013;9. doi: 10.1086/655472</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/655472</ArticleId><ArticleId IdType="pubmed">20632887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Peng G, Bai J, He B, Huang K, Hu X, et al. . Cytomegalovirus infection and relative risk of cardiovascular disease (Ischemic heart disease, stroke, and cardiovascular death): A meta-analysis of prospective studies up to 2016. J Am Heart Assoc (2017) 6(7). doi: 10.1161/JAHA.116.005025</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.116.005025</ArticleId><ArticleId IdType="pmc">PMC5586265</ArticleId><ArticleId IdType="pubmed">28684641</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrester JV. Ebola Virus and persistent chronic infection: when does replication cease? Ann Transl Med (2018) 6(Suppl 1):S39. doi: 10.21037/atm.2018.09.60</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.09.60</ArticleId><ArticleId IdType="pmc">PMC6291550</ArticleId><ArticleId IdType="pubmed">30613614</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Anglin K, Durstenfeld MS, Martin JN, Kelly JD, Hsue PY, et al. . Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun (2022) 7(1):95&#x2013;103. doi: 10.20411/pai.v7i1.518</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v7i1.518</ArticleId><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>
Geng LN BH, Shafer RW, Miglis MG, Yang PC. Case report of breakthrough long COVID and the use of nirmatrelvir-ritonavir (2022). Available at: https://www.scienceopen.com/document?vid=e7cc8eb6-98b5-4a69-a1af-09ace722cf4d.</Citation></Reference><Reference><Citation>
University S . Paxlovid for treatment of long covid (STOP-PASC) (2022). Available at: https://clinicaltrials.gov/ct2/show/NCT05576662.</Citation></Reference><Reference><Citation>
Kanecia Obie Zimmerman DU . SARS CoV-2 viral persistence study (PASC) - study of long COVID-19 (PASC) (2022). Available at: https://clinicaltrials.gov/ct2/show/NCT05595369.</Citation></Reference><Reference><Citation>Aleissa MM, Silverman EA, Paredes Acosta LM, Nutt CT, Richterman A, Marty FM. New perspectives on antimicrobial agents: Remdesivir treatment for COVID-19. Antimicrob Agents Chemother (2020) 65(1). doi: 10.1128/AAC.01814-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01814-20</ArticleId><ArticleId IdType="pmc">PMC7927874</ArticleId><ArticleId IdType="pubmed">33139290</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: A new candidate for COVID-19 treatment. Pharmacol Res Perspect (2022) 10(1):e00909. doi: 10.1002/prp2.909</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.909</ArticleId><ArticleId IdType="pmc">PMC8929331</ArticleId><ArticleId IdType="pubmed">34968008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobori H, Fukao K, Kuroda T, Anan N, Tashima R, Nakashima M, et al. . Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model. J Antimicrob Chemother (2022) 77. doi: 10.1093/jac/dkac257</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkac257</ArticleId><ArticleId IdType="pmc">PMC9384569</ArticleId><ArticleId IdType="pubmed">35914182</ArticleId></ArticleIdList></Reference><Reference><Citation>Leegwater E, Moes D, Bosma LBE, Ottens TH, van der Meer IM, van Nieuwkoop C, et al. . Population pharmacokinetics of remdesivir and GS-441524 in hospitalized COVID-19 patients. Antimicrob Agents Chemother (2022) 66(6):e0025422. doi: 10.1128/aac.00254-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00254-22</ArticleId><ArticleId IdType="pmc">PMC9211420</ArticleId><ArticleId IdType="pubmed">35647646</ArticleId></ArticleIdList></Reference><Reference><Citation>
FDA . FDA Updates on bebtelovimab (2022). Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-bebtelovimab.</Citation></Reference><Reference><Citation>Mumtaz A, Sheikh AAE, Khan AM, Khalid SN, Khan J, Nasrullah A, et al. . COVID-19 vaccine and long COVID: A scoping review. Life (Basel) (2022) 12(7). doi: 10.3390/life12071066</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12071066</ArticleId><ArticleId IdType="pmc">PMC9324565</ArticleId><ArticleId IdType="pubmed">35888154</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tran V PE, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: A target trial emulation using data from the ComPaRe e-cohort in France (2022). Available at: file:///Users/hectorbonilla/Downloads/SSRN-id3932953-2.pdf.</Citation></Reference><Reference><Citation>Nehme M, Braillard O, Salamun J, Jacquerioz F, Courvoisier DS, Spechbach H, et al. . Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV-2. J Gen Intern Med (2022) 37(6):1585&#x2013;8. doi: 10.1007/s11606-022-07443-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07443-2</ArticleId><ArticleId IdType="pmc">PMC8863092</ArticleId><ArticleId IdType="pubmed">35194744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. . Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. BMJ (2022) 377:e069676. doi: 10.1136/bmj-2021-069676</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Do vaccines protect against long COVID? what the data say. Nature (2021) 599(7886):546&#x2013;8. doi: 10.1038/d41586-021-03495-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03495-2</ArticleId><ArticleId IdType="pubmed">34815580</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators R-C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. . Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med (2021) 384(16):1491&#x2013;502. doi: 10.1056/NEJMoa2100433</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. . Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med (2021) 384(9):795&#x2013;807. doi: 10.1056/NEJMoa2031994</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. . Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature (2020) 584(7821):463&#x2013;9. doi: 10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonny TS, Patel EU, Zhu X, Bloch EM, Grabowski MK, Abraham AG, et al. . Cytokine and chemokine levels in coronavirus disease 2019 convalescent plasma. Open Forum Infect Dis (2021) 8(2):ofaa574. doi: 10.1093/ofid/ofaa574</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa574</ArticleId><ArticleId IdType="pmc">PMC7717355</ArticleId><ArticleId IdType="pubmed">33553467</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, Nylander AN, Ho HE, Lu S, et al. . Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm (2022) 9(5). doi: 10.1212/NXI.0000000000200003</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. . Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis (2021) 224(11):1839&#x2013;48. doi: 10.1093/infdis/jiab490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol (2022) 23(2):210&#x2013;6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. . The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med (2022) 3(6):100663. doi:&#xa0;10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz MAF, Neves P, Lima SS, Lopes JDC, Torres M, Vallinoto I, et al. . Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol (2022) 12:922422. doi: 10.3389/fcimb.2022.922422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, et al. . Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight (2022) 7(10). doi: 10.1172/jci.insight.157053</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157053</ArticleId><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Castaneda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, et al. . Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell (2022) 185(14):2452&#x2013;68 e16. doi: 10.1016/j.cell.2022.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertanto DM, Wiratama BS, Sutanto H, Wungu CDK. Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future. J Inflammation Res (2021) 14:3419&#x2013;28. doi: 10.2147/JIR.S322831</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S322831</ArticleId><ArticleId IdType="pmc">PMC8312605</ArticleId><ArticleId IdType="pubmed">34321903</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol (2020) 42(6):669&#x2013;80. doi: 10.1007/s00281-020-00827-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-020-00827-8</ArticleId><ArticleId IdType="pubmed">33219395</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. . Dexamethasone in hospitalized patients with covid-19. N Engl J Med (2021) 384(8):693&#x2013;704. doi:&#xa0;10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne A MS, Sharp C, Hamilton FW, Arnold DT. Impact of dexamethasone on persistent symptoms of COVID-19: An observational study. medRxiv (2021). doi:&#xa0;10.1101/2021.11.17.21266392v1</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21266392v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. . Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc (2021) 18(5):799&#x2013;806. doi: 10.1513/AnnalsATS.202008-1002OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202008-1002OC</ArticleId><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel N, Goyal N, Nagaraja R, Kumar R. Systemic corticosteroids for management of &#x2018;long-COVID&#x2019;: An evaluation after 3 months of treatment. Monaldi Arch Chest Dis (2021) 92(2). doi: 10.4081/monaldi.2021.1981</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2021.1981</ArticleId><ArticleId IdType="pubmed">34730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell (2022) 185(5):881&#x2013;95 e20. doi: 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. . Distinguishing features of long COVID identified through immune profiling. medRxiv (2022). doi: 10.1101/2022.08.09.22278592</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. (2016) 15(4):457&#x2013;65. doi: 10.1517/14740338.2016.1140743</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.2016.1140743</ArticleId><ArticleId IdType="pubmed">26789102</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, et al. . Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N Engl J Med (2021) 384(16):1503&#x2013;16. doi: 10.1056/NEJMoa2028700</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028700</ArticleId><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby LD, Kalanidhi S, Bonilla A, Subramanian A, Ballon JS, Bonilla H. Off label use of aripiprazole shows promise as a treatment for myalgic Encephalomyelitis/Chronic fatigue syndrome (ME/CFS): A retrospective study of 101 patients treated with a low dose of aripiprazole. J Transl Med (2021) 19(1):50. doi: 10.1186/s12967-021-02721-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-02721-9</ArticleId><ArticleId IdType="pmc">PMC7860172</ArticleId><ArticleId IdType="pubmed">33536023</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo O PP, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). In: Fatigue: Biomedicine, health &amp; behavior (2019) (Informa UK Limited: Taylor &amp; Francis Group; ). doi:&#xa0;10.1080/21641846.2019.1692770</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2019.1692770</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; An interventional pre-post study. Brain Behav Immun Health (2022) 24:100485. doi: 10.1016/j.bbih.2022.100485</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucic N, Racki V, Sverko R, Vidovic T, Grahovac I, Mrsic-Pelcic J. Immunometabolic modulatory role of naltrexone in BV-2 microglia cells. Int J Mol Sci (2021) 22(16). doi: 10.3390/ijms22168429</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168429</ArticleId><ArticleId IdType="pmc">PMC8395119</ArticleId><ArticleId IdType="pubmed">34445130</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Kim JG, Park JW, Koch M, Horvath TL, Lee BJ. Hypothalamic TLR2 triggers sickness behavior via a microglia-neuronal axis. Sci Rep (2016) 6:29424. doi: 10.1038/srep29424</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep29424</ArticleId><ArticleId IdType="pmc">PMC4942617</ArticleId><ArticleId IdType="pubmed">27405276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. . Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature (2021) 595(7868):565&#x2013;71. doi: 10.1038/s41586-021-03710-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic Encephalomyelitis/Chronic fatigue syndrome patients. Front Immunol (2019) 10:2545. doi: 10.3389/fimmu.2019.02545</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02545</ArticleId><ArticleId IdType="pmc">PMC6834647</ArticleId><ArticleId IdType="pubmed">31736966</ArticleId></ArticleIdList></Reference><Reference><Citation>Selfridge BR, Wang X, Zhang Y, Yin H, Grace PM, Watkins LR, et al. . Structure-activity relationships of (+)-Naltrexone-Inspired toll-like receptor 4 (TLR4) antagonists. J Med Chem (2015) 58(12):5038&#x2013;52. doi: 10.1021/acs.jmedchem.5b00426</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b00426</ArticleId><ArticleId IdType="pmc">PMC4634939</ArticleId><ArticleId IdType="pubmed">26010811</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNFalpha production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors. Front Immunol (2017) 8:809. doi: 10.3389/fimmu.2017.00809</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00809</ArticleId><ArticleId IdType="pmc">PMC5504148</ArticleId><ArticleId IdType="pubmed">28744288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Tate AM, Gluck D, Rosenson RS, Goonewardena SN. Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. Eur Heart J Cardiovasc Pharmacother. (2022) 8(4):402&#x2013;5. doi: 10.1093/ehjcvp/pvac014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvac014</ArticleId><ArticleId IdType="pmc">PMC8903502</ArticleId><ArticleId IdType="pubmed">35179184</ArticleId></ArticleIdList></Reference><Reference><Citation>
Nacul L. Low-dose naltrexone for post-COVID fatigue syndrome. Vancouver, Canada: University of British Columbia;  (2022). Available at: https://clinicaltrials.gov/ct2/show/NCT05430152.</Citation></Reference><Reference><Citation>de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: Translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs (2015) 29(9):773&#x2013;99. doi: 10.1007/s40263-015-0278-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-015-0278-3</ArticleId><ArticleId IdType="pmc">PMC4602118</ArticleId><ArticleId IdType="pubmed">26346901</ArticleId></ArticleIdList></Reference><Reference><Citation>
FDA . Aripipraxole (Abilify). APPROVED AGREED-UPON LABELING (2004). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21436s002lbl.pdf.</Citation></Reference><Reference><Citation>Zhang Y, Chen Y, Wu J, Manaenko A, Yang P, Tang J, et al. . Activation of dopamine D2 receptor suppresses neuroinflammation through alphaB-crystalline by inhibition of NF-kappaB nuclear translocation in experimental ICH mice model. Stroke (2015) 46(9):2637&#x2013;46. doi: 10.1161/STROKEAHA.115.009792</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.115.009792</ArticleId><ArticleId IdType="pmc">PMC4550518</ArticleId><ArticleId IdType="pubmed">26251254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil CH, Kim YR, Lee HJ, Jung DH, Shin HK, Choi BT. Aripiprazole exerts a neuroprotective effect in mouse focal cerebral ischemia. Exp Ther Med (2018) 15(1):745&#x2013;50. doi:&#xa0;10.3892/etm.2017.5443</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.5443</ArticleId><ArticleId IdType="pmc">PMC5772374</ArticleId><ArticleId IdType="pubmed">29399080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato-Kasai M, Kato TA, Ohgidani M, Mizoguchi Y, Sagata N, Inamine S, et al. . Aripiprazole inhibits polyI:C-induced microglial activation possibly via TRPM7. Schizophr Res (2016) 178(1-3):35&#x2013;43. doi: 10.1016/j.schres.2016.08.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2016.08.022</ArticleId><ArticleId IdType="pubmed">27614570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T, Mizoguchi Y, Monji A, Horikawa H, Suzuki SO, Seki Y, et al. . Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J Neurochem (2008) 106(2):815&#x2013;25. doi: 10.1111/j.1471-4159.2008.05435.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05435.x</ArticleId><ArticleId IdType="pubmed">18429930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato TA, Monji A, Yasukawa K, Mizoguchi Y, Horikawa H, Seki Y, et al. . Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: Implication for antioxidative psychotropic actions via microglia. Schizophr Res (2011) 129(2-3):172&#x2013;82. doi: 10.1016/j.schres.2011.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2011.03.019</ArticleId><ArticleId IdType="pubmed">21497059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobis J, Rykaczewska-Czerwinska M, Swietochowska E, Gorczyca P. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep (2015) 67(2):353&#x2013;9. doi: 10.1016/j.pharep.2014.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharep.2014.09.007</ArticleId><ArticleId IdType="pubmed">25712663</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, et al. . Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur J Intern Med (2021) 92:55&#x2013;70. doi: 10.1016/j.ejim.2021.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, Catalfamo CJ, Farland LV, Ernst KC, Jacobs ET, Klimentidis YC, et al. . Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. PloS One (2021) 16(8):e0254347. doi: 10.1371/journal.pone.0254347</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254347</ArticleId><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Zhang Y, Tang X, Ge S, Wen H, Zeng J, et al. . Evidence on acupuncture therapies is underused in clinical practice and health policy. BMJ (2022) 376:e067475. doi: 10.1136/bmj-2021-067475</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-067475</ArticleId><ArticleId IdType="pmc">PMC8868048</ArticleId><ArticleId IdType="pubmed">35217525</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurek M, Rayner C, Freyer A, Taylor S, Jarte L, MacDermott N, et al. . Recommendations for the recognition, diagnosis, and management of long COVID: A Delphi study. Br J Gen Pract (2021) 71(712):e815&#x2013;e25. doi: 10.3399/BJGP.2021.0265</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGP.2021.0265</ArticleId><ArticleId IdType="pmc">PMC8510689</ArticleId><ArticleId IdType="pubmed">34607799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Yang JW, Lin LT, Huang J, Wang XR, Su XT, et al. . Acupuncture attenuates inflammation in microglia of vascular dementia rats by inhibiting miR-93-Mediated TLR4/MyD88/NF-kappaB signaling pathway. Oxid Med Cell Longev (2020) 2020:8253904. doi:&#xa0;10.1155/2020/8253904</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8253904</ArticleId><ArticleId IdType="pmc">PMC7441436</ArticleId><ArticleId IdType="pubmed">32850002</ArticleId></ArticleIdList></Reference><Reference><Citation>sha NAG . A traditional thechnique for modern practice. (2013) (Elsevier Health Sciences; ). 158.</Citation></Reference><Reference><Citation>Nielsen A, Gua sha Bg. Fascial dysfunction:Traditional East Asian instrument-assisted manual therapies. (2018) (Elsevier Health Sciences; ).</Citation></Reference><Reference><Citation>Xia ZW, Zhong WW, Meyrowitz JS, Zhang ZL. The role of heme oxygenase-1 in T cell-mediated immunity: The all encompassing enzyme. Curr Pharm Des (2008) 14(5):454&#x2013;64. doi: 10.2174/138161208783597326</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161208783597326</ArticleId><ArticleId IdType="pubmed">18289072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. . Persistent clotting protein pathology in long COVID/Post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol (2021) 20(1):172. doi: 10.1186/s12933-021-01359-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al. . Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/Post-acute sequelae of COVID-19 (PASC). Cardiovasc Diabetol (2022) 21(1):148. doi: 10.1186/s12933-022-01579-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E VC, Laubscher GJ, Kotze MJ, Moremi K OS, Watson LR, Rajaratnam K, et al. . Combined triple treatment of brin amyloid microclots and platelet pathology in individuals with Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) can resolve their persistent symptoms. Research Square (2021). doi:&#xa0;10.21203/rs.3.rs-1205453/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1205453/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, et al. . Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet (2022) 399(10319):50&#x2013;9. doi: 10.1016/S0140-6736(21)02392-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02392-8</ArticleId><ArticleId IdType="pmc">PMC8673881</ArticleId><ArticleId IdType="pubmed">34921756</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. . Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA (2020) 324(13):1317&#x2013;29. doi:&#xa0;10.1001/jama.2020.17022</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17022</ArticleId><ArticleId IdType="pmc">PMC7489418</ArticleId><ArticleId IdType="pubmed">32876697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Wu X, Wen W, Lan P. Gut microbiome alterations in COVID-19. Genomics Proteomics Bioinf (2021) 19(5):679&#x2013;88. doi: 10.1016/j.gpb.2021.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2021.09.004</ArticleId><ArticleId IdType="pmc">PMC8478109</ArticleId><ArticleId IdType="pubmed">34560321</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, et al. . Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut (2022) 71(3):544&#x2013;52. doi: 10.1136/gutjnl-2021-325989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Haran JP, Bradley E, Zeamer AL, Cincotta L, Salive MC, Dutta P, et al. . Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight (2021) 6(20). doi: 10.1172/jci.insight.152346</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.152346</ArticleId><ArticleId IdType="pmc">PMC8564890</ArticleId><ArticleId IdType="pubmed">34403368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wastyk HC, Fragiadakis GK, Perelman D, Dahan D, Merrill BD, Yu FB, et al. . Gut-microbiota-targeted diets modulate human immune status. Cell (2021) 184(16):4137&#x2013;53 e14. doi: 10.1016/j.cell.2021.06.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.019</ArticleId><ArticleId IdType="pmc">PMC9020749</ArticleId><ArticleId IdType="pubmed">34256014</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam H, Chamberlain TC, Mui AL, Little JP. Elevated interleukin-10 levels in COVID-19: Potentiation of pro-inflammatory responses or impaired anti-inflammatory action? Front Immunol (2021) 12:677008. doi: 10.3389/fimmu.2021.677008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.677008</ArticleId><ArticleId IdType="pmc">PMC8255680</ArticleId><ArticleId IdType="pubmed">34234779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirmiran P, Bahadoran Z, Gaeini Z. Common limitations and challenges of dietary clinical trials for translation into clinical practices. Int J Endocrinol Metab (2021) 19(3):e108170. doi: 10.5812/ijem.108170</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/ijem.108170</ArticleId><ArticleId IdType="pmc">PMC8453651</ArticleId><ArticleId IdType="pubmed">34567133</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitolins MZ, Case TL. What makes nutrition research so difficult to conduct and interpret? Diabetes Spectr (2020) 33(2):113&#x2013;7. doi: 10.2337/ds19-0077</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/ds19-0077</ArticleId><ArticleId IdType="pmc">PMC7228817</ArticleId><ArticleId IdType="pubmed">32425447</ArticleId></ArticleIdList></Reference><Reference><Citation>Damania B, Kenney SC, Raab-Traub N. Epstein-Barr Virus: Biology and clinical disease. Cell (2022) 185(20):3652&#x2013;70. doi: 10.1016/j.cell.2022.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.08.026</ArticleId><ArticleId IdType="pmc">PMC9529843</ArticleId><ArticleId IdType="pubmed">36113467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. . Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science (2022) 375(6578):296&#x2013;301. doi: 10.1126/science.abj8222</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. . Clonally expanded b cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature (2022) 603(7900):321&#x2013;7. doi: 10.1038/s41586-022-04432-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04432-7</ArticleId><ArticleId IdType="pmc">PMC9382663</ArticleId><ArticleId IdType="pubmed">35073561</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens (2021) 10(6). doi: 10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder DM, Buck AM, Beck-Engeser G, et al. . Impact of pre-existing chronic viral infection and reactivation on the development of long COVID. J Clin Invest (2022). doi:&#xa0;10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E, Reshkova V, Kumanova capital AC, Raleva S, Alexandrova D, Capo N, et al. . Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic small ie, cyrillicncephalomyelitis/chronic fatigue syndrome. J Med Virol (2020) 92. doi: 10.1002/jmv.25744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25744</ArticleId><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, Montoya JG. Use of valganciclovir in patients with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol (2006) 37 Suppl 1:S33&#x2013;8. doi: 10.1016/S1386-6532(06)70009-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(06)70009-9</ArticleId><ArticleId IdType="pubmed">17276366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J. Early growth response gene upregulation in Epstein-Barr virus (EBV)-associated myalgic Encephalomyelitis/Chronic fatigue syndrome (ME/CFS). Biomolecules (2020) 10(11). doi: 10.3390/biom10111484</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10111484</ArticleId><ArticleId IdType="pmc">PMC7692278</ArticleId><ArticleId IdType="pubmed">33114612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr Virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome. Front Immunol (2021) 12:656797. doi: 10.3389/fimmu.2021.656797</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.656797</ArticleId><ArticleId IdType="pmc">PMC8634673</ArticleId><ArticleId IdType="pubmed">34867935</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L, et al. . Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. J Med Virol (2012) 84(12):1967&#x2013;74. doi: 10.1002/jmv.23411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23411</ArticleId><ArticleId IdType="pubmed">23080504</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, et al. . Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J Med Virol (2013) 85(12):2101&#x2013;9. doi: 10.1002/jmv.23713</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23713</ArticleId><ArticleId IdType="pubmed">23959519</ArticleId></ArticleIdList></Reference><Reference><Citation>Yager JE, Magaret AS, Kuntz SR, Selke S, Huang ML, Corey L, et al. . Valganciclovir for the suppression of Epstein-Barr virus replication. J Infect Dis (2017) 216(2):198&#x2013;202. doi: 10.1093/infdis/jix263</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix263</ArticleId><ArticleId IdType="pmc">PMC5854009</ArticleId><ArticleId IdType="pubmed">28838145</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, et al. . Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. (2011) 17(6):901&#x2013;7. doi: 10.1016/j.bbmt.2010.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2010.10.003</ArticleId><ArticleId IdType="pubmed">20950702</ArticleId></ArticleIdList></Reference><Reference><Citation>Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, et al. . CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncolytics. (2020) 18:504&#x2013;24. doi: 10.1016/j.omto.2020.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2020.08.005</ArticleId><ArticleId IdType="pmc">PMC7479496</ArticleId><ArticleId IdType="pubmed">32953984</ArticleId></ArticleIdList></Reference><Reference><Citation>
Virios Therapeutics I . IMC-2 long-COVID treatment trial (2022). Available at: https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/.</Citation></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. . Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest (2023) 133(3). doi: 10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole E, Neves TC, Oliveira MT, Sinclair J, da Silva MCC. Human cytomegalovirus interleukin 10 homologs: Facing the immune system. Front Cell Infect Microbiol (2020) 10:245. doi: 10.3389/fcimb.2020.00245</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00245</ArticleId><ArticleId IdType="pmc">PMC7296156</ArticleId><ArticleId IdType="pubmed">32582563</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman D, Jojic V, Sharma S, Shen-Orr SS, Angel CJ, Onengut-Gumuscu S, et al. . Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med (2015) 7(281):281ra43. doi: 10.1126/scitranslmed.aaa2293</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa2293</ArticleId><ArticleId IdType="pmc">PMC4505610</ArticleId><ArticleId IdType="pubmed">25834109</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JL, Villacreses R, Nagpal P, Guo J, Pezzulo AA, Thurman AL, et al. . Quantitative chest CT assessment of small airways disease in post-acute SARS-CoV-2 infection. Radiology (2022) 304(1):185&#x2013;92. doi: 10.1148/radiol.212170</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.212170</ArticleId><ArticleId IdType="pmc">PMC9270680</ArticleId><ArticleId IdType="pubmed">35289657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhooria S. A study of the efficacy and safety of pirfenidone vs. nintedanib in the treatment of fibrotic lung disease after coronavirus disease-19 pneumonia. ClinicalTrialsgov (2021).</Citation></Reference><Reference><Citation>
Maria Molina IdIBdB . Pirfenidone compared to placebo in post-COVID19 pulmonary fibrosis COVID-19 (FIBRO-COVID) (2020). Available at: https://clinicaltrials.gov/ct2/show/NCT04607928.</Citation></Reference><Reference><Citation>
Sahajal Dhooria PIoMEaR . Pirfenidone vs. nintedanib for fibrotic lung disease after coronavirus disease-19 pneumonia (PINCER) (2021). Available at: https://clinicaltrials.gov/ct2/show/NCT04856111.</Citation></Reference><Reference><Citation>Franquet T, Gimenez A, Ketai L, Mazzini S, Rial A, Pomar V, et al. . Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT. Eur Radiol (2022) 32(7):4427&#x2013;36. doi: 10.1007/s00330-022-08580-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-022-08580-2</ArticleId><ArticleId IdType="pmc">PMC8884095</ArticleId><ArticleId IdType="pubmed">35226158</ArticleId></ArticleIdList></Reference><Reference><Citation>
PureTech . LYT-100 in post-acute COVID-19 respiratory disease (2020). Available at: https://www.clinicaltrials.gov/ct2/show/NCT04652518.</Citation></Reference><Reference><Citation>Orfei MD, Porcari DE, D&#x2019;Arcangelo S, Maggi F, Russignaga D, Ricciardi E. A new look on long-COVID effects: The functional brain fog syndrome. J Clin Med (2022) 11(19). doi: 10.3390/jcm11195529</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11195529</ArticleId><ArticleId IdType="pmc">PMC9573330</ArticleId><ArticleId IdType="pubmed">36233392</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Zhou F, Hou W, Silver Z, Wong CY, Chang O, et al. . The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: A meta-analysis. Ann N Y Acad Sci (2021) 1486(1):90&#x2013;111. doi: 10.1111/nyas.14506</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14506</ArticleId><ArticleId IdType="pmc">PMC7675607</ArticleId><ArticleId IdType="pubmed">33009668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahrami HA, Alhaj OA, Humood AM, Alenezi AF, Fekih-Romdhane F, AlRasheed MM, et al. . Sleep disturbances during the COVID-19 pandemic: A systematic review, meta-analysis, and meta-regression. Sleep Med Rev (2022) 62:101591. doi: 10.1016/j.smrv.2022.101591</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2022.101591</ArticleId><ArticleId IdType="pmc">PMC8782754</ArticleId><ArticleId IdType="pubmed">35131664</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriquez-Beltran M, Labarca G, Cigarroa I, Enos D, Lastra J, Nova-Lamperti E, et al. . Sleep health and the circadian rest-activity pattern four months after COVID-19. J Bras Pneumol (2022) 48(3):e20210398. doi: 10.36416/1806-3756/e20210398</Citation><ArticleIdList><ArticleId IdType="doi">10.36416/1806-3756/e20210398</ArticleId><ArticleId IdType="pmc">PMC9064633</ArticleId><ArticleId IdType="pubmed">35508066</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri A, Srinivasan A, Sundar IK. COVID-19: Sleep, circadian rhythms and immunity - repurposing drugs and chronotherapeutics for SARS-CoV-2. Front Neurosci (2021) 15:674204. doi: 10.3389/fnins.2021.674204</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.674204</ArticleId><ArticleId IdType="pmc">PMC8249936</ArticleId><ArticleId IdType="pubmed">34220430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichniak A, Kania A, Sieminski M, Cubala WJ. Melatonin as a potential adjuvant treatment for COVID-19 beyond sleep disorders. Int J Mol Sci (2021) 22(16). doi: 10.3390/ijms22168623</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168623</ArticleId><ArticleId IdType="pmc">PMC8395320</ArticleId><ArticleId IdType="pubmed">34445329</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. . Myalgic encephalomyelitis: International consensus criteria. J Intern Med (2011) 270(4):327&#x2013;38. doi: 10.1111/j.1365-2796.2011.02428.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>McManimen SL, Jason LA. Post-exertional malaise in patients with ME and CFS with comorbid fibromyalgia. SRL Neurol Neurosurg (2017) 3(1):22&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5464757</ArticleId><ArticleId IdType="pubmed">28603794</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A, Jason LA. Meta-analysis investigating post-exertional malaise between patients and controls. J Health Psychol (2020) 25(13-14):2053&#x2013;71. doi: 10.1177/1359105318784161</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1359105318784161</ArticleId><ArticleId IdType="pmc">PMC7440642</ArticleId><ArticleId IdType="pubmed">29974812</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bonilla H QT, Tiwari A, Bonilla AE, Miglis M, Yang P, Eggert L, et al. . Myalgic Encephalomyelitis/Chronic fatigue syndrome (ME/CFS) is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic . medRxiv. Available at: https://wwwmedrxivorg/content/101101/2022080322278363v1fullpdf (Accessed August 4, 2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998690</ArticleId><ArticleId IdType="pubmed">36908615</ArticleId></ArticleIdList></Reference><Reference><Citation>
Authority PHS . Energy point chart (2021). Available at: http://www.phsa.ca/health-info-site/Documents/post_covid-19-Living_in_your_Energy_Envelope_Tool.pdf.</Citation></Reference><Reference><Citation>
Physio LC . Resources (2022). Available at: https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-rehab-allied-health-practice-considerations-post-covid.pdf.</Citation></Reference><Reference><Citation>
Axcella Health I . Efficacy, safety, tolerability of AXA1125 in fatigue after COVID-19 infection (2021). Available at: https://clinicaltrials.gov/ct2/show/NCT05152849.</Citation></Reference><Reference><Citation>
Axcella Health I . Axcella announces highly promising results from phase 2a placebo controlled clinical trial for long COVID (2022). Available at: https://ir.axcellatx.com/news-releases/news-release-details/axcella-announces-highly-promising-results-phase-2a-placebo.</Citation></Reference><Reference><Citation>Hansen KS, Mogensen TH, Agergaard J, Schiottz-Christensen B, Ostergaard L, Vibholm LK, et al. . High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: A randomized, phase 2, crossover trial. Lancet Reg Health Eur (2022) 84, 100539. doi:&#xa0;10.1016/j.lanepe.2022.100539</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100539</ArticleId><ArticleId IdType="pmc">PMC9627534</ArticleId><ArticleId IdType="pubmed">36337437</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad A, Janda A, Renk H, Stich M, Frieh P, Kaier K, et al. . Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational cohort study. EBioMedicine (2022) 84:104245. doi: 10.1016/j.ebiom.2022.104245</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104245</ArticleId><ArticleId IdType="pmc">PMC9495281</ArticleId><ArticleId IdType="pubmed">36155957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>